NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics is supported by accelerating next-generation sequencing and MRD adoption, with PanTracer LBx gaining MolDX coverage and RaDaR ST expanding into the clinical oncology channel, both of which should deepen reimbursement-backed growth. Its 1Q26 revenue of $186.7 million rose 11.1% year over year, NGS revenue increased 26%, and EBITDA margin reached 5%, while management also guided to a roughly 9% 2Q26 revenue increase and positive free cash flow in 2026. The company’s broad clinical test menu, major insurance contracts, and more than 70% exposure to community oncology create a strong distribution moat, while margin expansion potential and a valuation near 2.7x EV/revenue support a constructive outlook.

NeoGenomics is facing a structurally difficult operating backdrop because its oncology diagnostics business depends on a complex mix of CLIA, state, FDA-adjacent, and CMS reimbursement rules that can change without warning and quickly pressure revenue and costs. The company has already been affected by Medicare reimbursement and billing changes, and the cited risks point to further downside from surprise pricing cuts, uneven reimbursement trends, and broader macro uncertainty that can delay hospital and research spending. Competitive risk is also high, as new NGS and informatics offerings from rivals could weaken legacy testing growth, while acquisition integration and regulatory hurdles add execution risk to a small-cap profile.